Article

Kidney and urethral cancer

Presented by Michael A. O'Donnell, MD, University of Iowa, Iowa City

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
1 expert in this video
Clinical Benefits of BPH Treatments
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
CISTO: Radical cystectomy has key role in recurrent high-grade NMIBC
May 1st 2025

CISTO: Radical cystectomy has key role in recurrent high-grade NMIBC

Hannah Clarke
Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.
Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD
Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
FDA updates in urology: April 2025
May 1st 2025

FDA updates in urology: April 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from April 2025.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
Site Logo
April 29th 2025

Advancing Patient Care: Innovations in Bladder Cancer

Sponsored by Pfizer
© 2025 MJH Life Sciences

All rights reserved.